

Funder	Project Title	Funding	Strategic Plan Objective	Institution
National Institutes of Health	2/3-Atomoxetine placebo and parent training in autism	\$358,106	Q4.S.F	The Ohio State University
Autism Speaks	Genome-wide association study of autism characterized by developmental regression	\$127,458	Q3.S.E	Cincinnati Children's Hospital Medical Center
National Institutes of Health	A randomized control study of relationship focused intervention with young children with ASD	\$274,750	Q4.S.F	Case Western Reserve University
National Institutes of Health	Identification and functional assessment of autism susceptibility genes	\$262,704	Q3.L.B	The Research Institute at Nationwide Children's Hospital
National Institutes of Health	Selective disruption of hippocampal dentate granule cells in autism: Impact of PTEN deletion	\$375,000	Q2.S.E	Cincinnati Children's Hospital Medical Center
Autism Speaks	Safe Signals: Teaching high functioning young adults with autism spectrum disorders about community safety behaviors	\$24,978	Q5.L.B	The Ohio State University Medical Center
National Institutes of Health	2/2 Development of a screening interview for research studies of ASD	\$364,291	Q1.S.A	Cincinnati Children's Hospital Medical Center
Autism Speaks	Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine	\$44,917	Q4.L.C	The Ohio State University